Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 1;11(8):4163-4168.
eCollection 2018.

Loss of E-cadherin expression in recurrent non-invasive urothelial carcinoma of the bladder

Mecdi Gurhan Balci  1 , Mahir Tayfur  1
Affiliations

Loss of E-cadherin expression in recurrent non-invasive urothelial carcinoma of the bladder

Mecdi Gurhan Balci et al. Int J Clin Exp Pathol. .

Abstract

Background: Bladder cancer is the most common malignancy in the urothelial tract. Invasive cancer has a poor prognosis compared to non-invasive cancer, and identifying the cancer type is useful in determining the most appropriate treatment. In this study, the expression ratios of E-cadherin in non-invasive urothelial carcinoma of the bladder were investigated. The goal of the study was to predict possible invasion in the recurrence of these cases.

Material and methods: Seventy-two recurrent non-invasive cases of urothelial carcinoma of the bladder were retrospectively analyzed. An immunohistochemical study of E-cadherin was performed of the baseline tissue sections. An evaluation was carried out of the intensity of membranous staining of E-cadherin and the percentage of cells that stained positive.

Results: Invasive cancer was identified in the recurrence material of 14 of the 72 urothelial carcinomas of the bladder that were originally non-invasive based on the baseline samples. The rate of invasion in the recurrence material was significantly higher in cases in which the loss of E-cadherin expression was observed.

Conclusion: If E-cadherin expression is negative or weak, close clinical follow-up of patients is necessary, even if the initial diagnosis is non-invasive urothelial carcinoma of the bladder. This is because the rate of invasion in these cases is higher in recurrent cases.

Keywords: E-cadherin expression; Urothelial carcinoma of the bladder; invasion.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Group 1 (negative staining with E-cadherin): E-cadherin staining score 2 (× 200).
Figure 2
Figure 2
Group 2 (weakly positive E-cadherin staining): E-cadherin staining score 6 (× 200).
Figure 3
Figure 3
Group 3 (strongly positive E-cadherin staining): E-cadherin staining score 12 (× 200).
Figure 4
Figure 4
Non-invasive urothelial carcinoma (arrow) (HE × 200).
Figure 5
Figure 5
The invasion of lamina propria in the recurrent material (arrow) (HE × 200).
Figure 6
Figure 6
The invasion of muscularis propria in the recurrent material (arrow) (HE × 200).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108. - PubMed
    1. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–61. - PubMed
    1. Black PC. Fine-tuning risk stratification for non-muscle-invasive bladder cancer. Eur Urol. 2016;69:70–1. - PubMed
    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–75. - PubMed

LinkOut - more resources